Co-Section Head, Inflammatory Bowel Diseases
Director, Inflammatory Bowel Diseases Research and Advanced Inflammatory Bowel Diseases Fellowship
Department of Gastroenterology, Hepatology and Nutrition
Digestive Diseases and Surgery Institute
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
This activity is intended for gastroenterologists, and specialist nurse practitioners, and physician assistants who care for patients with ulcerative colitis (UC).
Several new advanced therapies with novel mechanisms of action have been approved by the US Food and Drug Administration (FDA) for the treatment of moderate to severe UC. The latest addition to the pharmacotherapy toolbox is the class of selective sphingosine 1-phosphate receptor (S1PR) modulators. Best practices for the use of these novel oral therapies, including placement within treatment algorithms, have yet to be established and, therefore, comprise an important gap within management. This activity is a multimedia training program consisting of 3 circuits that will boost your endurance and strengthen your expertise with respect to the use of this novel class of agents within the management of UC.
Upon completion of this activity, participants should be able to:
- Describe the unique mechanism of action of S1P receptor modulators as it relates to UC treatment
- Summarize the evolving efficacy and safety data for current and emerging oral S1P modulators for moderate-to-severely active UC
- Employ evidence-based clinical decision-making, based on evolving clinical data, and available practice guidelines for the treatment and monitoring of moderate-to-severe UC
- Develop personalized therapeutic strategies for patients with moderate-to-severe UC based on individual patient characteristics, preferences, and potential barriers to healthcare access
Faculty and Disclosure of Conflicts of Interest
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Florian Rieder, MD: Consultant: Adiso, Adnovate, Agomab, Allergan, AbbVie, Arena, Astra Zeneca, Boehringer-Ingelheim, Celgene/BMS, CDISC, Celsius, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Granite, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis Limited, Index Pharma, Landos, Jannsen, Koutif, Mestag, Metacrine, Mopac, Morphic, Organovo, Origo, Palisade, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Sanofi, Surmodics, Surrozen, Takeda, Techlab, Teva, Theravance, Thetis, UCB, Ysios, 89Bio; Other (Funding): NIH, Helmsley Charitable Trust, Crohn’s and Colitis Foundation, UCB, Pliant, BMS, AbbVie, Pfizer, Boehringer Ingelheim, Morphic, Kenneth Rainin Foundation
The PACE planners and others have no relevant financial relationships to disclose with ineligible companies. The Integritas planners and others have no relevant financial relationships to disclose with ineligible companies.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Integritas Communications. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Coninuing Professinoal Development activity is 1.0 contact hour.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions to Receive Credit
To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a minimum score of 75% on the posttest, and complete the program evaluation..
There is no fee for this educational activity.
CME Questions – PACE Contact Information
For information about the accreditation of this program, please contact PACE https://partnersed.com/
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at email@example.com.
1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
512 MB of RAM (1 GB recommended)
Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
For HTML Client – Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)
1.83 GHz Intel Core Duo or faster processor
512 MB of RAM (1 GB recommended)
MAC OS X 10.12, 10.13 and 10.14
Mozilla Firefox, Apple Safari, Google Chrome
For HTML Client – Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)